Upon administration of SJZ, LZ, and FZLZ, the expression of PPAR-α, CPT-1, and CPT-2 was upregulated while that of SREBP-1c was reduced (P < 0.05) to various extents, indicating that the three decoctions ameliorated the symptoms of NAFLD by promoting PPAR-α and inhibiting SREBP-1c. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.